AAP
TRVI icon

Arax Advisory Partners’s Trevi Therapeutics TRVI Stock Holding History

Arax Advisory Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.62K Buy
+194
New +$2.82K ﹤0.01% 4673
2026
Q1 		– Sell
-206
Closed -$2.58K – 4328
2025
Q4 		$2.58K Buy
206
+21
+11% +$243 ﹤0.01% 3168
2025
Q3 		$1.69K Buy
+185
New +$1.39K ﹤0.01% 3152

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Arax Advisory Partners's TRVI Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 194 shares worth $3.62K. The stake represents ﹤0.01% of the portfolio and ranks #4673 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in TRVI as recently as Q4 2025.

Arax Advisory Partners first reported a position in TRVI in Q3 2025 and has held it in 3 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Arax Advisory Partners held 194 shares of Trevi Therapeutics worth $3.62K as of Q2 2026.
  • Trevi Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Trevi Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4673 holding.
  • Arax Advisory Partners first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.